12:00 AM
 | 
Feb 20, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Botox onabotulinumtoxinA regulatory update

The U.K.'s NICE said it needs additional information before it can recommend the use of Botox onabotulinumtoxinA from Allergan to treat chronic migraine. In draft guidance, the committee said Botox's benefit was "small" and the results were "confounded" by a large...

Read the full 183 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >